Beijing Changfeng Hospital

"Changfeng" breaking waves at the right time, sailing straight across the vast sea
--Changfeng Group striding forward


Beijing Changfeng Hospital Co., Ltd. was established in 2008. It is a company specializing in hospital investment and management, as well as comprehensive diagnosis and treatment services for hemangioma and other diseases. It has successfully listed on the National Equities Exchange and Quotations (NEEQ, also known as the New Third Board) as a joint-stock company, with stock code 870890.
The predecessor of the company was the Ezhou Traditional Chinese Medicine Hemangioma Specialty Hospital, which had over ten years of experience in treating hemangiomas, and was the only hemangioma specialty hospital in the province approved by the Hubei Provincial Department of Health according to the standards of a tertiary hospital. Within just five years of its establishment, through new construction, mergers and acquisitions, and trusteeship, the company established more than ten wholly-owned medical institutions in Beijing, Shanghai, Zhengzhou, Jinan, and other places, including Beijing Fengtai Changfeng Hospital, Shanghai Cao'an Hospital, Zhengzhou Changfeng Hospital, Jinan Minsheng Hospital, Chongqing Changfeng Hospital, Nanchang Qingyunpu Changfeng Hospital, Ezhou Traditional Chinese Medicine Hemangioma Specialty Hospital, Jingzhou Wenjie Hospital, and Changsha Changfeng Hospital. It also owns the Beijing Zhonglian Changfeng International Hemangioma Research Institute, dedicated to the research and innovation of hemangioma treatment methods.
Beijing Changfeng Hospital Management Co., Ltd. is rapidly expanding while establishing its own medical institutions. It also conducts technical and project cooperation with many top domestic and international hospitals, including Beijing 301 Hospital, 302 Hospital, Peking Union Medical College Hospital, General Hospital of the People's Armed Police Force, Air Force General Hospital, Hospital of the General Political Department of the People's Liberation Army, Shanghai Ninth People's Hospital, Fourth Military Medical University, the Second Affiliated Hospital of Xi'an Jiaotong University, and West China Clinical Medical College of Sichuan University, maintaining good relationships for technical and academic exchanges. It has also hired experts from these hospitals to regularly give lectures, conduct consultations, and perform surgical demonstrations at its affiliated hospitals, greatly improving the company's technical level and academic status in the treatment of vascular surgery, hemangiomas, and other vascular diseases.
The company adheres to the development philosophy of "high starting point, high standard, high positioning," and fully promotes modern management, modern marketing, and modern technical concepts in medical institutions. It has successively passed ISO9000 certification and JCI certification. The company accommodates medical management teams, expert teams, and marketing teams with practical and forward-looking management experience from all over the country. Through market refinement, the company has achieved rapid, steady, and sustainable development. In the third year after its establishment, annual business revenue exceeded 100 million yuan, making it a modern medical management group with first-class experts, first-class technology, first-class management, and first-class service.
The company always adheres to "building the institution with science and technology" and "prospering the institution with talents," introducing a large number of outstanding medical professionals with specialized expertise, of which senior and intermediate professional title medical talents account for 70% of the total business personnel. Combined with world-advanced human resource management solutions, the company has established a scientific talent echelon module, and the high-quality and efficient talent echelon construction provides sufficient reserve talents, cultivating batches of technical backbones and core forces. The company takes "everything for patients, serving patients wholeheartedly" as its service purpose, and "people-oriented" as its management philosophy, bringing good news to the majority of patients with first-class technology, first-class equipment, and first-class service.
It is believed that in the future, Changfeng Group will not only become a leader in the treatment of hemangiomas and other fields, but also become the most standardized medical management group with international standards in China, writing a new chapter for China's medical and health services!